Adjusted logistic regression model for predictors of average doses of prednisone >7.5 mg/day during the months 2–12 of follow-up after systemic lupus erythematosus (SLE) diagnosis, in the whole cohort and limited to patients with a baseline SLEDAI of ≥6
| OR | 95% CI | |
|---|---|---|
| Whole cohort (n=223) | ||
| Prednisone-1 | ||
| No | Reference | Reference |
| Low | 1.43 | 0.38 to 5.3 |
| Medium | 5.8 | 2.3 to 14.3 |
| High | 10.8 | 3.9 to 29.8 |
| Methyl-prednisolone bolus (yes/no) | 0.32 | 0.10 to 1.02 |
| Immunosuppressive drugs (yes/no) | 2.88 | 1.21 to 6.8 |
| Weeks on HCQ | 1.00 | 0.99 to 1.00 |
| Baseline SLEDAI | 1.07 | 1.01 to 1.14 |
| Nephritis | 1.67 | 0.53 to 5.1 |
| Age at diagnosis | 0.98 | 0.96 to 1.01 |
| Baseline SLEDAI of ≥6 (n=158) | ||
| Prednisone-1 | ||
| No | Reference | Reference |
| Low | 1.49 | 0.29 to 7.5 |
| Medium | 4.6 | 1.65 to 12.9 |
| High | 11.4 | 3.5 to 37.03 |
| Methyl-prednisolone bolus (yes/no) | 0.13 | 0.03 to 0.57 |
| Immunosuppressive drugs (yes/no) | 2.39 | 0.85 to 6.6 |
| Weeks on HCQ | 1.00 | 0.99 to 1.00 |
| Baseline SLEDAI | 1.06 | 0.98 to 1.13 |
| Nephritis | 3.64 | 0.96 to 13.8 |
| Age at diagnosis | 0.98 | 0.95 to 1.01 |
Prednisone-1: average prednisone dose during the first month.
HCQ, hydroxychloroquine; SLEDAI, SLE Disease Activity Index.